MDS research criteria for prodromal Parkinson's disease.
Identifieur interne : 000401 ( PubMed/Corpus ); précédent : 000400; suivant : 000402MDS research criteria for prodromal Parkinson's disease.
Auteurs : Daniela Berg ; Ronald B. Postuma ; Charles H. Adler ; Bastiaan R. Bloem ; Piu Chan ; Bruno Dubois ; Thomas Gasser ; Christopher G. Goetz ; Glenda Halliday ; Lawrence Joseph ; Anthony E. Lang ; Inga Liepelt-Scarfone ; Irene Litvan ; Kenneth Marek ; José Obeso ; Wolfgang Oertel ; C Warren Olanow ; Werner Poewe ; Matthew Stern ; Günther DeuschlSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.
English descriptors
- KwdEn :
- MESH :
- diagnosis : Parkinson Disease.
- standards : Societies, Scientific.
- Humans, Prodromal Symptoms, Severity of Illness Index.
Abstract
This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible. Given the lack of clear neuroprotective/disease-modifying therapy for prodromal PD, these criteria were developed for research purposes only. The criteria are based upon the likelihood of prodromal disease being present with probable prodromal PD defined as ≥80% certainty. Certainty estimates rely upon calculation of an individual's risk of having prodromal PD, using a Bayesian naïve classifier. In this methodology, a previous probability of prodromal disease is delineated based upon age. Then, the probability of prodromal PD is calculated by adding diagnostic information, expressed as likelihood ratios. This diagnostic information combines estimates of background risk (from environmental risk factors and genetic findings) and results of diagnostic marker testing. In order to be included, diagnostic markers had to have prospective evidence documenting ability to predict clinical PD. They include motor and nonmotor clinical symptoms, clinical signs, and ancillary diagnostic tests. These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available.
DOI: 10.1002/mds.26431
PubMed: 26474317
Links to Exploration step
pubmed:26474317Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">MDS research criteria for prodromal Parkinson's disease.</title><author><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name><affiliation><nlm:affiliation>Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tuebingen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B" last="Postuma">Ronald B. Postuma</name><affiliation><nlm:affiliation>Department of Neurology, Montreal General Hospital, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H" last="Adler">Charles H. Adler</name><affiliation><nlm:affiliation>The Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Bloem, Bastiaan R" sort="Bloem, Bastiaan R" uniqKey="Bloem B" first="Bastiaan R" last="Bloem">Bastiaan R. Bloem</name><affiliation><nlm:affiliation>Department of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Nijmegen, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Chan, Piu" sort="Chan, Piu" uniqKey="Chan P" first="Piu" last="Chan">Piu Chan</name><affiliation><nlm:affiliation>Xuanwu Hospital of Capitol of Medical University, Beijing, China.</nlm:affiliation></affiliation></author><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><nlm:affiliation>Hopital De La Salpetriere, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gasser, Thomas" sort="Gasser, Thomas" uniqKey="Gasser T" first="Thomas" last="Gasser">Thomas Gasser</name><affiliation><nlm:affiliation>Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tuebingen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name><affiliation><nlm:affiliation>Rush University Medical Center, Chicago, Illinois, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Halliday, Glenda" sort="Halliday, Glenda" uniqKey="Halliday G" first="Glenda" last="Halliday">Glenda Halliday</name><affiliation><nlm:affiliation>Neuroscience Research Australia & University of NSW, Randwick, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Joseph, Lawrence" sort="Joseph, Lawrence" uniqKey="Joseph L" first="Lawrence" last="Joseph">Lawrence Joseph</name><affiliation><nlm:affiliation>Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name><affiliation><nlm:affiliation>Division of Neurology, Toronto Western Hospital, Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Liepelt Scarfone, Inga" sort="Liepelt Scarfone, Inga" uniqKey="Liepelt Scarfone I" first="Inga" last="Liepelt-Scarfone">Inga Liepelt-Scarfone</name><affiliation><nlm:affiliation>Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tuebingen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name><affiliation><nlm:affiliation>Department of Neurosciences, University of California San Diego, La Jolla, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name><affiliation><nlm:affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Obeso, Jose" sort="Obeso, Jose" uniqKey="Obeso J" first="José" last="Obeso">José Obeso</name><affiliation><nlm:affiliation>University of Navarra-FIMA, Pamplona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name><affiliation><nlm:affiliation>Department of Neurology, Philipps University of Marburg, Marburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name><affiliation><nlm:affiliation>Department of Neurology, The Mount Sinai Hospital, New York, New York, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><nlm:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name><affiliation><nlm:affiliation>Penn Neurological Institute, Philadelphia, Pennsylvania, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Deuschl, Gunther" sort="Deuschl, Gunther" uniqKey="Deuschl G" first="Günther" last="Deuschl">Günther Deuschl</name><affiliation><nlm:affiliation>Department of Neurology, Christian-Albrechts University, Kiel, Germany.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26474317</idno><idno type="pmid">26474317</idno><idno type="doi">10.1002/mds.26431</idno><idno type="wicri:Area/PubMed/Corpus">000401</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000401</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">MDS research criteria for prodromal Parkinson's disease.</title><author><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name><affiliation><nlm:affiliation>Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tuebingen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B" last="Postuma">Ronald B. Postuma</name><affiliation><nlm:affiliation>Department of Neurology, Montreal General Hospital, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H" last="Adler">Charles H. Adler</name><affiliation><nlm:affiliation>The Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Bloem, Bastiaan R" sort="Bloem, Bastiaan R" uniqKey="Bloem B" first="Bastiaan R" last="Bloem">Bastiaan R. Bloem</name><affiliation><nlm:affiliation>Department of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Nijmegen, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Chan, Piu" sort="Chan, Piu" uniqKey="Chan P" first="Piu" last="Chan">Piu Chan</name><affiliation><nlm:affiliation>Xuanwu Hospital of Capitol of Medical University, Beijing, China.</nlm:affiliation></affiliation></author><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><nlm:affiliation>Hopital De La Salpetriere, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gasser, Thomas" sort="Gasser, Thomas" uniqKey="Gasser T" first="Thomas" last="Gasser">Thomas Gasser</name><affiliation><nlm:affiliation>Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tuebingen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name><affiliation><nlm:affiliation>Rush University Medical Center, Chicago, Illinois, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Halliday, Glenda" sort="Halliday, Glenda" uniqKey="Halliday G" first="Glenda" last="Halliday">Glenda Halliday</name><affiliation><nlm:affiliation>Neuroscience Research Australia & University of NSW, Randwick, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Joseph, Lawrence" sort="Joseph, Lawrence" uniqKey="Joseph L" first="Lawrence" last="Joseph">Lawrence Joseph</name><affiliation><nlm:affiliation>Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name><affiliation><nlm:affiliation>Division of Neurology, Toronto Western Hospital, Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Liepelt Scarfone, Inga" sort="Liepelt Scarfone, Inga" uniqKey="Liepelt Scarfone I" first="Inga" last="Liepelt-Scarfone">Inga Liepelt-Scarfone</name><affiliation><nlm:affiliation>Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tuebingen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name><affiliation><nlm:affiliation>Department of Neurosciences, University of California San Diego, La Jolla, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name><affiliation><nlm:affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Obeso, Jose" sort="Obeso, Jose" uniqKey="Obeso J" first="José" last="Obeso">José Obeso</name><affiliation><nlm:affiliation>University of Navarra-FIMA, Pamplona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name><affiliation><nlm:affiliation>Department of Neurology, Philipps University of Marburg, Marburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name><affiliation><nlm:affiliation>Department of Neurology, The Mount Sinai Hospital, New York, New York, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><nlm:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name><affiliation><nlm:affiliation>Penn Neurological Institute, Philadelphia, Pennsylvania, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Deuschl, Gunther" sort="Deuschl, Gunther" uniqKey="Deuschl G" first="Günther" last="Deuschl">Günther Deuschl</name><affiliation><nlm:affiliation>Department of Neurology, Christian-Albrechts University, Kiel, Germany.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Humans</term><term>Parkinson Disease (diagnosis)</term><term>Prodromal Symptoms</term><term>Severity of Illness Index</term><term>Societies, Scientific (standards)</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Societies, Scientific</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Prodromal Symptoms</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible. Given the lack of clear neuroprotective/disease-modifying therapy for prodromal PD, these criteria were developed for research purposes only. The criteria are based upon the likelihood of prodromal disease being present with probable prodromal PD defined as ≥80% certainty. Certainty estimates rely upon calculation of an individual's risk of having prodromal PD, using a Bayesian naïve classifier. In this methodology, a previous probability of prodromal disease is delineated based upon age. Then, the probability of prodromal PD is calculated by adding diagnostic information, expressed as likelihood ratios. This diagnostic information combines estimates of background risk (from environmental risk factors and genetic findings) and results of diagnostic marker testing. In order to be included, diagnostic markers had to have prospective evidence documenting ability to predict clinical PD. They include motor and nonmotor clinical symptoms, clinical signs, and ancillary diagnostic tests. These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26474317</PMID><DateCreated><Year>2015</Year><Month>10</Month><Day>17</Day></DateCreated><DateCompleted><Year>2016</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2015</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>MDS research criteria for prodromal Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>1600-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26431</ELocationID><Abstract><AbstractText>This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible. Given the lack of clear neuroprotective/disease-modifying therapy for prodromal PD, these criteria were developed for research purposes only. The criteria are based upon the likelihood of prodromal disease being present with probable prodromal PD defined as ≥80% certainty. Certainty estimates rely upon calculation of an individual's risk of having prodromal PD, using a Bayesian naïve classifier. In this methodology, a previous probability of prodromal disease is delineated based upon age. Then, the probability of prodromal PD is calculated by adding diagnostic information, expressed as likelihood ratios. This diagnostic information combines estimates of background risk (from environmental risk factors and genetic findings) and results of diagnostic marker testing. In order to be included, diagnostic markers had to have prospective evidence documenting ability to predict clinical PD. They include motor and nonmotor clinical symptoms, clinical signs, and ancillary diagnostic tests. These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available.</AbstractText><CopyrightInformation>© 2015 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Postuma</LastName><ForeName>Ronald B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Montreal General Hospital, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Charles H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>The Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bloem</LastName><ForeName>Bastiaan R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Piu</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Xuanwu Hospital of Capitol of Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Hopital De La Salpetriere, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasser</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Glenda</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia & University of NSW, Randwick, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Anthony E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Division of Neurology, Toronto Western Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liepelt-Scarfone</LastName><ForeName>Inga</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Litvan</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marek</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obeso</LastName><ForeName>José</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Navarra-FIMA, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oertel</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Philipps University of Marburg, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olanow</LastName><ForeName>C Warren</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Mount Sinai Hospital, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poewe</LastName><ForeName>Werner</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Penn Neurological Institute, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deuschl</LastName><ForeName>Günther</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Christian-Albrechts University, Kiel, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2016 Jan;12(1):10-1</RefSource><PMID Version="1">26714657</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="Y">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012958" MajorTopicYN="N">Societies, Scientific</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">prodromal</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>04</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>08</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>08</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26474317</ArticleId><ArticleId IdType="doi">10.1002/mds.26431</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000401 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000401 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26474317
|texte= MDS research criteria for prodromal Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26474317" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |